Analysts Set Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Target Price at $51.40

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $51.40.

A number of research analysts have issued reports on the stock. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Evercore began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price target on the stock. Jefferies Financial Group boosted their price objective on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Weiss Ratings assumed coverage on Hemab Therapeutics in a report on Thursday, August 13th. They issued a “sell (d+)” rating for the company. Finally, Wedbush raised their target price on Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th.

Hemab Therapeutics Price Performance

Shares of NASDAQ COAG opened at $39.40 on Friday. The firm has a market capitalization of $1.84 billion and a price-to-earnings ratio of -1.59. Hemab Therapeutics has a 1-year low of $23.00 and a 1-year high of $55.42. The stock has a fifty day moving average of $46.13.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.17). On average, equities research analysts predict that Hemab Therapeutics will post -3.09 earnings per share for the current year.

Insider Transactions at Hemab Therapeutics

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was bought at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the purchase, the insider owned 6,444,637 shares in the company, valued at $160,987,032.26. This trade represents a 0.96% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Institutional Investors Weigh In On Hemab Therapeutics

Several institutional investors have recently bought and sold shares of COAG. Squarepoint Ops LLC bought a new position in Hemab Therapeutics in the 2nd quarter valued at about $230,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Hemab Therapeutics in the 2nd quarter worth approximately $688,000. Opaleye Management Inc. bought a new position in shares of Hemab Therapeutics in the second quarter valued at approximately $1,750,000. Braidwell LP bought a new position in shares of Hemab Therapeutics in the second quarter valued at approximately $5,877,000. Finally, Citadel Advisors LLC bought a new stake in Hemab Therapeutics during the second quarter worth approximately $19,226,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious and underserved bleeding disorders. The company aims to create therapies that address limitations of existing approaches, including the need for frequent administration and the challenges associated with complex blood-product-based treatments.

Its lead investigational program, HMB-001, is being developed for Glanzmann thrombasthenia, a rare inherited disorder in which platelets do not function properly and can cause severe bleeding.